Clinical trial NCT06185816: Non-Invasive Pulsed Radiofrequency for the Treatment of Neuropathic Pain
Official title: Non-Invasive Pulsed Radiofrequency for the Treatment of Neuropathic Pain
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE2
PHASE3
Conditions: Pain, Nerve
Lead sponsor: Stanford University
Sponsor class: OTHER
First posted: 2023-12-29
Enrollment: 95
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to examine non-invasive pulsed radiofrequency (NIPRF) and the effect it has on chronic neuropathic pain. Chronic neuropathic pain after peripheral nerve injury most often occurs in the context of post-traumatic or post-surgical pain. It is often treated with nerve blocks, prescription medication, physical therapy, neuromodulation, and surgery. The study team will be examining the efficacy of NIPRF and determining if it would be an appropriate treatment for chronic neuropathic pain after peripheral nerve injury.The Stimpod used in the present study is FDA approved and will be used for on label purposes.


Eligibility criteria: Inclusion Criteria:

* -Adults aged 18 or older with clinically diagnosed chronic neuropathic pain after peripheral injury defined as persistent or recurrent neuropathic pain caused by a peripheral nerve lesion, history of a plausible nerve trauma, pain onset in temporal relation to the trauma, and pain distribution within the innervation territory of a peripheral nerve (or nerves). Negative and positive sensory symptoms or signs must be compatible with the innervation territory of the affected nerve. Can be posttraumatic, post-surgical, nerve compression, nerve ischemia with or without loss of motor function
* Positive response (at least 50% pain relief) to diagnostic nerve block at the suspected site of CNP-PI.
* Continued pain despite conservative therapy for a minimum of 12 weeks
* Stable dosage of analgesic medications for at least 30 days, and willingness to refrain from trialing new analgesic medications for three weeks after randomization
* Worst pain intensity of ≥5/10 on the Numeric Rating Scale (NRS) of Pain (0-10) at the CNP-PI site at enrollment
* English-speaking
* Ability and willingness to complete online and phone assessments

Exclusion Criteria:

* Conditions causing inability to complete assessments (education, cognitive ability, mental status, medical status)
* Cancer diagnosis, active malignant neoplasm (metastatic or local) or evidence of paraneoplastic syndrome
* Painful polyneuropathy (e.g., metabolic, autoimmune, familial, infectious disease, environmental toxins, treatment with neurotoxic drug)
* Chronic central neuropathic pain (e.g., spinal cord injury, brain injury, multiple sclerosis)
* Peripheral vascular disease
* Diabetic neuropathy
* Other active implantable devices (e.g., implantable cardioverter defibrillator, spinal cord stimulator, dorsal root ganglion stimulator, sacral nerve stimulator, deep brain stimulator, intrathecal pump)
* Pregnancy, breastfeeding, or planning to conceive
* Systemic infection or local infection at the anticipated NIPRF treatment sites
* Interventional procedure and/or surgery to treat CNP-PI in the last 30 days (subjects should be enrolled 30 days after last procedure, for prior ablative treatment must be enrolled at least 3 months after last procedure)
* Epilepsy
* Metal implants within the target treatment area of the NIPRF.

Primary outcomes:
measure: Treatment Response Rate
timeFrame: After Three Weeks of Starting Treatment
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: